Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBluecross Idaho Ustekinumab Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy N/A

    Intravenous Ustekinumab for Inflammatory Bowel Disease

    Customize your policy alerts

    Sign up for all Bluecross Idaho policy alerts

    Know when Bluecross Idaho releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-benefit coverage and prior authorization for intravenous ustekinumab induction in adults with moderately to severely active Crohn's disease or ulcerative colitis; subcutaneous ustekinumab is handled under the pharmacy benefit.

    Policy Summary
    PayerBluecross Idaho
    PolicyIntravenous Ustekinumab for Inflammatory Bowel Disease
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and apply the medical-necessity criteria before intravenous ustekinumab induction.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added HCPCS code J3590 for unclassified biologics and identified Yesintek (ustekinumab-kfce) in the 2026 medical-benefit update.

    The policy history states that the policy was extensively revised and that language was updated for consistency across policies.

    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered inflammatory bowel disease indications
    18+Minimum age for coverage
    260/390/520 mgWeight-based induction doses
    3Non-medical-necessity risk categories
    3Ustekinumab-related HCPCS codes listed

    Medical Necessity and Coverage Criteria

    Initial intravenous induction

    Intravenous ustekinumab induction may be considered medically necessary when all of the following are met.

    Initial intravenous induction criteria

    • Preferred product: The request is for a preferred product in accordance with the member's plan benefits.

      For Standard, QHP, and Access Formulary members, the preferred product is Yesintek (ustekinumab); for Premium Formulary members, it is Stelara (ustekinumab); for individuals without a Blue Cross of Idaho pharmacy benefit, it is Stelara (ustekinumab).

    • Tuberculosis screening: The individual has had a tuberculosis screening test within 6 months of initiating therapy confirming no active tuberculosis.Within 6 months before initiation

      If latent tuberculosis infection is present, treatment must be started before use. If switching from another targeted immune modulator that required TB screening at initiation and there are no new risk factors, repeat TB screening is not necessary.

    • Adult age: The individual is 18 years of age or older.18 years or older
    • Qualifying diagnosis

      • Ulcerative colitis: Moderate to severely active ulcerative colitis.
      • Crohn's disease: Moderate to severely active Crohn's disease.
    • Weight-based intravenous induction dose: The prescriber will initiate dosing with a single intravenous infusion using the dose corresponding to body weight.55 kg or less: 260 mg; more than 55 kg to 85 kg: 390 mg; more than 85 kg: 520 mg
    • No prohibited combination therapy: Ustekinumab will not be used in combination with any other biologic DMARD or targeted synthetic DMARD.

      See Appendix 1 referenced by the policy.

    Adult inflammatory bowel disease indications

    Coverage may be considered for an adult patient with one of the following moderately to severely active inflammatory bowel disease indications:

    Adult inflammatory bowel disease indication

    • Crohn's disease: The patient has moderately to severely active Crohn's disease.Moderately to severely active
    • Ulcerative colitis: The patient has moderately to severely active ulcerative colitis.Moderately to severely active

    Subcutaneous ustekinumab is outside the scope of this medical policy. It is processed under the pharmacy benefit and is subject to applicable utilization-management requirements and formulary coverage restrictions.

    Ustekinumab used in combination with phototherapy is not medically necessary.

    Do not administer Stelara to a patient with a clinically important active infection until the infection has resolved or is adequately treated. Stelara should not be administered to a patient with active tuberculosis.

    A request for a non-preferred ustekinumab product, as determined by the member's applicable benefit, is not medically necessary.

    Ustekinumab is not medically necessary for an individual with a history of posterior reversible encephalopathy syndrome.

    Ustekinumab is not medically necessary for an individual with active or untreated latent tuberculosis, hepatitis B, another active serious infection, or a history of recurrent infections. Evaluate for tuberculosis before initiating therapy; latent tuberculosis must be treated before administration, and patients should be monitored for active tuberculosis during and after treatment.

    Requests that do not meet the listed coverage criteria, and requests for all other indications, are not medically necessary.

    Billing and Coding Information

    CPTCPT
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour.
    CPTCPT
    96372Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.
    HCPCSHCPCS
    J3357Ustekinumab, for subcutaneous injection, 1 mg.
    J3358Ustekinumab, for intravenous injection, 1 mg.
    J3590Unclassified biologics.
    Q5100Injection, ustekinumab-kfce (Yesintek), biosimilar, 1 mg.
    ICD-10-CMICD-10
    K50.0-K50.919Crohn's disease code range.
    K51.0-K51.919Ulcerative Colitis code range.
    ICD-10-PCSICD-10
    .Type of.
    .Place of.
    .Service.
    Body weight for intravenous induction dose
    Body weight55 kg or less
    Intravenous induction dose260 mg
    AdministrationSingle intravenous infusion
    Crohn's disease quantity during induction and maintenance transition
    Body weight55 kg or less
    Intravenous induction quantity2 IV vials for 1 dose

    Provider Requirements and Safety Actions

    Billing Rule

    Initial Intravenous Induction Authorization

    Authorize the initial ustekinumab intravenous induction under the medical benefit only when the applicable medical-necessity criteria are met. The prescriber must initiate treatment with one weight-based intravenous infusion.

    • 260 mg for individuals weighing 55 kg or less
    • 390 mg for individuals weighing more than 55 kg to 85 kg
    • 520 mg for individuals weighing more than 85 kg
    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Stelara to ensure safe, clinically appropriate, and cost-effective use while maintaining optimal therapeutic outcomes.

    Policy Background

    Ustekinumab is a human interleukin-12 (IL-12) and interleukin-23 (IL-23) antagonist that reduces inflammatory activity. This policy addresses intravenous induction for adults with moderately to severely active Crohn's disease or ulcerative colitis; subsequent subcutaneous therapy is handled under the applicable benefit. Because treatment may increase the risk of infection and reactivation of latent infection, patients should be evaluated for tuberculosis before treatment.

    Key Definitions

    Ustekinumab
    DrugUstekinumab
    TargetInterleukin-12 (IL-12) and interleukin-23 (IL-23)
    Drug classHuman interleukin-12 and interleukin-23 antagonist
    Qualifying inflammatory bowel disease
    Patient populationAdult
    Crohn's diseaseModerate to severely active Crohn's disease
    Ulcerative colitisModerate to severely active ulcerative colitis

    Initial Therapy

    Initial intravenous ustekinumab induction

    Intravenous ustekinumab induction may be considered medically necessary when all listed requirements are met.

    • Preferred product by benefit: Use Yesintek (ustekinumab) for Standard, QHP, and Access Formulary members; Stelara (ustekinumab) for Premium Formulary members; or Stelara (ustekinumab) for individuals without a Blue Cross of Idaho pharmacy benefit.
    • Tuberculosis screening: Obtain TB screening within 6 months before initiation confirming no active tuberculosis, subject to the policy's exception for switching from another targeted immune modulator without new risk factors.Within 6 months before initiation
    • Adult qualifying patient: The individual is at least 18 years old and has moderately to severely active Crohn's disease or ulcerative colitis.

    Quantity and Dose Limits

    Ustekinumab quantity limit
    Weight range55 kg or less
    Intravenous quantity2 IV vials for one dose
    Subcutaneous quantity1 subcutaneous syringe per 56 days
    Ustekinumab quantity limit
    Weight rangeMore than 55 kg to 85 kg
    Intravenous quantity3 IV vials for one dose
    Subcutaneous quantity1 subcutaneous syringe per 56 days
    Policy Summary
    PayerBluecross Idaho
    PolicyIntravenous Ustekinumab for Inflammatory Bowel Disease
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and apply the medical-necessity criteria before intravenous ustekinumab induction.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaBilling and Coding InformationProvider Requirements and Safety ActionsPolicy BackgroundKey DefinitionsInitial TherapyQuantity and Dose Limits
    Subcutaneous quantity1 subcutaneous syringe per 56 days
    Continuation quantity
    Applicable conditionsCrohn's disease or ulcerative colitis
    Strength90 mg subcutaneous syringe
    Continuation quantity1 subcutaneous syringe per 56 days
    Documentation Required

    Required Clinical and Treatment Documentation

    Document the preferred product, TB status, age, qualifying diagnosis, and treatment history before requesting ustekinumab. For individuals with a Blue Cross of Idaho pharmacy benefit, product selection depends on the applicable formulary; individuals without that pharmacy benefit require Stelara.

    • Standard, QHP, and Access Formulary: Yesintek (ustekinumab)
    • Premium Formulary: Stelara (ustekinumab)
    • Without a Blue Cross of Idaho pharmacy benefit: Stelara (ustekinumab)
    • Document TB screening within 6 months before initiation confirming no active TB, unless the individual is switching from another targeted immune modulator that required TB screening at initiation and has no new risk factors
    • Document that the individual is 18 years of age or older
    • Document moderate to severely active ulcerative colitis or moderate to severely active Crohn’s disease
    • Document treatment history, including any switch from another targeted immune modulator and whether latent TB treatment is indicated
    Note

    TB Evaluation and Monitoring

    Evaluate every patient for tuberculosis infection before initiating Stelara and monitor closely for signs and symptoms of active TB during and after treatment.

    • Do not administer Stelara to patients with active tuberculosis
    • Initiate treatment of latent tuberculosis before administering Stelara
    • Consider anti-tuberculosis therapy before initiation when a past history of latent or active TB exists and an adequate treatment course cannot be confirmed
    Note

    Malignancy and Skin-Cancer Monitoring

    Stelara may increase the risk of malignancy. Monitor all patients for non-melanoma skin cancer and follow patients with elevated risk particularly closely.

    • Patients older than 60 years
    • Patients with a history of prolonged immunosuppressant therapy
    • Patients with a history of PUVA treatment
    Denial Risk

    Circumstances That May Result in a Non-Medical-Necessity Determination

    Ustekinumab intravenous infusion and subcutaneous injection requests may be determined not medically necessary when the product or clinical circumstances do not meet policy requirements.

    • Request is for a non-preferred ustekinumab product
    • Use is in combination with phototherapy
    • History of posterior reversible encephalopathy syndrome
    • Active or untreated latent tuberculosis, hepatitis B, or another active serious infection, or a history of recurrent infections
    • Criteria are not met or the request is for any other indication
    Denial Risk

    Avoid Combination Immunomodulator Therapy

    Do not use ustekinumab in combination with another biologic disease-modifying antirheumatic drug or targeted synthetic disease-modifying antirheumatic drug.

    • Avoid concurrent biologic DMARD therapy
    • Avoid concurrent targeted synthetic DMARD therapy
    Denial Risk

    Active Infection

    Do not administer Stelara to a patient with a clinically important active infection until the infection resolves or is adequately treated.

    • Serious infections requiring hospitalization may include diverticulitis, cellulitis, pneumonia, appendicitis, sepsis, and cholecystitis
    • Assess for bacterial, fungal, and viral infections and reactivation of latent infections
    Denial Risk

    Tuberculosis Restrictions

    Stelara must not be administered for active TB, and latent TB must be treated before Stelara is given.

    • Active tuberculosis: prohibit administration
    • Latent tuberculosis: initiate treatment before administration
    • Past latent or active TB with no confirmed adequate treatment course: consider anti-tuberculosis therapy before initiation
    Ustekinumab
    DrugUstekinumab
    TargetInterleukin-12 (IL-12) and interleukin-23 (IL-23)
    Mechanism classificationHuman interleukin-12 and interleukin-23 antagonist
    Age 18 or older
  1. Single intravenous infusion: Administer 260 mg at 55 kg or less, 390 mg at more than 55 kg to 85 kg, or 520 mg at more than 85 kg.260 mg, 390 mg, or 520 mg by body weight
  2. No prohibited concomitant therapy: Do not combine ustekinumab with another biologic DMARD or targeted synthetic DMARD.
  3. Initial therapy for inflammatory bowel disease

    Adult patients with moderately to severely active Crohn's disease or moderately to severely active ulcerative colitis may be considered for initial ustekinumab therapy when prior authorization and applicable infection and tuberculosis safety requirements are completed.

    Initial therapy for inflammatory bowel disease: The patient is an adult with moderately to severely active Crohn's disease or moderately to severely active ulcerative colitis, and required prior authorization and infection and tuberculosis safety evaluation are completed.Moderately to severely active disease

    The policy does not provide additional initial-therapy sequencing criteria.

    Ustekinumab quantity limit
    Weight rangeMore than 85 kg
    Intravenous quantity4 IV vials for one dose
    Subcutaneous quantity1 subcutaneous syringe per 56 days
    Ustekinumab continuation quantity
    Applicable conditionsCrohn's disease or ulcerative colitis
    Strength90 mg subcutaneous syringe
    Quantity and interval1 subcutaneous syringe per 56 days